Skip to main content Help with accessibility Skip to main navigation

EMPAGLIFLOZIN, ERTUGLIFLOZIN, CANAGLIFLOZIN, and DAPAGLIFLOZIN as MONOTHERAPIES in type 2 diabetes: a multiple prescribing statement

CCG Approval Status:

Ha
Kn
Li
SF
SS
SH
Wa
WL
Wi
Date Added: 23 - Sep - 2021
Body System:
Green
EMPAGLIFLOZIN, ERTUGLIFLOZIN, CANAGLIFLOZIN, and DAPAGLIFLOZIN as MONOTHERAPIES in type 2 diabetes: a multiple prescribing statement

The Pan Mersey Area Prescribing Committee recommends the prescribing ofCANAGLIFLOZIN, DAPAGLIFLOZIN, EMPAGLIFLOZIN and ERTUGLIFLOZIN as
MONOTHERAPIES as options for treating type 2 diabetes in adults in accordance with NICE TA390 and TA572.

Static